Development of BMP2 Neurotrophic Therapy for Parkinson’s Disease

Project description

A new neurotrophic factor for Parkinson's disease

Parkinson's disease (PD) affects millions of people worldwide, and it is estimated that this number will have doubled by 2030 given the ageing demographic. Despite years of research, there is no therapy for PD. The EU-funded BMPARK project is investigating the potential of bone morphogenetic protein 2 (BMP2) as a neurotrophic factor to protect midbrain dopaminergic neurons in the brains of PD patients. Using a rat model of the disease, scientists will evaluate the efficacy of BMP2 in halting the progressive loss of dopaminergic neurons and improving motor function. The project's results will decipher the mode of BMP2 action and contribute to the future development of clinical strategies for PD.

Fields of science

• natural sciences › biological sciences › neurobiology
• natural sciences › biological sciences › biochemistry › biomolecules › proteins
• medical and health sciences › basic medicine › neurology › parkinson

Keywords

• Neurotrophic factors
• Parkinson’s Disease
• alpha-synuclein
• neurite growth
• bone morphogenetic protein

Programme(s)

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Topic(s)

• MSCA-IF-2019 - Individual Fellowships

Call for proposal

H2020-MSCA-IF-2019

See other projects for this call

Funding Scheme

MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)

Coordinator

UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK

Net EU contribution

€ 184 590,72

Address

Western Road
T12 YN60 Cork
Ireland

Region

Ireland › Southern › South-East

Activity type

Higher or Secondary Education Establishments

Links

Other funding

€ 0,00